State University of New York System

About: State University of New York System is a education organization based out in Albany, New York, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 54077 authors who have published 78070 publications receiving 2985160 citations.

Cross-National Associations Between Gender and Mental Disorders in the World Health Organization World Mental Health Surveys

Abstract: Epidemiological surveys have consistently documented significantly higher rates of anxiety and mood disorders among women than men1, 2 and significantly higher rates of externalizing and substance use disorders among men than women.3–5 Although a number of biological, psychosocial, and biopsychosocial hypotheses have been proposed to account for these patterns,6–8 evidence that gender differences in depression9, 10 and substance use11–13 have narrowed in a number of countries has led to a special interest in the “gender roles” hypothesis. The latter asserts that gender differences in the prevalence of mental disorders are due to differences in the typical stressors, coping resources, and opportunity structures for expressing psychological distress made available differentially to women and men in different countries at different points in history.14, 15 Consistent with this hypothesis, evidence of decreasing gender differences in depression and substance use has been found largely in countries where the roles of women have improved in terms of opportunities for employment, access to birth control, and other indicators of increasing gender role equality, while trend studies in countries where gender roles have been more static11, 16 or over periods of historical time when gender role changes have been small17 have failed to document a reduction in gender differences in depression or substance use. Most research aimed at investigating the gender roles hypothesis has focused on individual-level variation in roles in a single country at a single point in time.18–20 This approach is limited in three ways. First, selection bias into roles due to pre-existing mental illness (e.g., women with agoraphobia having a higher probability than other women of becoming homemakers rather than seeking employment outside the home) confounds attempts to evaluate the causal effects of gender roles. Second, gender differences are largely confined to differences in lifetime risk, with much less evidence for gender differences in recent prevalence among lifetime cases.21 This means that investigation of the determinants of gender difference should focus on lifetime first onset rather than on the recent prevalence that has been the focus of most studies. Third, as the gender roles hypothesis is a hypothesis about the effects of social context, a rigorous test of the hypothesis requires an analysis of societal-level time-space variation rather than analysis of the individual-level variation that has been the focus of most studies. A small number of cross-national comparative studies have examined spatial variation in gender differences in depression22 and alcohol abuse13 at a point in time or, more rarely, at two points in time.11 Although these studies raised the possibility that gender roles might be associated with variation in the magnitude of gender differences in these outcomes, they were unable to test this hypothesis due to the small number of cross-sectional country-level observations included in the analyses. The current report provides a more direct test of the gender roles hypothesis by analyzing community epidemiological data collected from respondents surveyed in 15 countries as part of the World Health Organization (WHO) World Mental Health (WMH) Survey Initiative.21 Previous cross-national comparisons of gender differences in mental illness focused on cross-sectional differences. We, in comparison, use retrospective reports obtained in the WMH surveys about lifetime occurrence and age-of-onset of mental disorders in different birth cohorts to study time-space variation in lifetime risk. Specifically, we examine both variation across cohorts within a single country (i.e., temporal variation) and variation across countries within a single cohort (i.e., special variation) in lifetime risk of mental disorders as a function of time-space variation in the traditionality of gender roles. Lifetime risk is the focus rather than recent prevalence even though accuracy of reporting is doubtlessly better for recent episodes than lifetime occurrence in order to address the fact that gender differences in lifetime risk are much more robust than gender differences in current prevalence among lifetime cases

The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases.

Abstract: Homologs of the chromatin-bound yeast silent information regulator 2 (SIR2) protein are found in organisms from all biological kingdoms. SIR2 itself was originally discovered to influence mating-type control in haploid cells by locus-specific transcriptional silencing. Since then, SIR2 and its homologs have been suggested to play additional roles in suppression of recombination, chromosomal stability, metabolic regulation, meiosis, and aging. Considering the far-ranging nature of these functions, a major experimental goal has been to understand the molecular mechanism(s) by which this family of proteins acts. We report here that members of the SIR2 family catalyze an NAD–nicotinamide exchange reaction that requires the presence of acetylated lysines such as those found in the N termini of histones. Significantly, these enzymes also catalyze histone deacetylation in a reaction that absolutely requires NAD, thereby distinguishing them from previously characterized deacetylases. The enzymes are active on histone substrates that have been acetylated by both chromatin assembly-linked and transcription-related acetyltransferases. Contrary to a recent report, we find no evidence that these proteins ADP-ribosylate histones. Discovery of an intrinsic deacetylation activity for the conserved SIR2 family provides a mechanism for modifying histones and other proteins to regulate transcription and diverse biological processes.

Structure, Function, and Control of Phosphoinositide-Specific Phospholipase C

Abstract: Phosphoinositide-specific phospholipase C (PLC) subtypes β, γ, and δ comprise a related group of multidomain phosphodiesterases that cleave the polar head groups from inositol lipids. Activated by ...

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.

Abstract: Importance Hydroxychloroquine, with or without azithromycin, has been considered as a possible therapeutic agent for patients with coronavirus disease 2019 (COVID-19). However, there are limited data on efficacy and associated adverse events. Objective To describe the association between use of hydroxychloroquine, with or without azithromycin, and clinical outcomes among hospital inpatients diagnosed with COVID-19. Design, Setting, and Participants Retrospective multicenter cohort study of patients from a random sample of all admitted patients with laboratory-confirmed COVID-19 in 25 hospitals, representing 88.2% of patients with COVID-19 in the New York metropolitan region. Eligible patients were admitted for at least 24 hours between March 15 and 28, 2020. Medications, preexisting conditions, clinical measures on admission, outcomes, and adverse events were abstracted from medical records. The date of final follow-up was April 24, 2020. Exposures Receipt of both hydroxychloroquine and azithromycin, hydroxychloroquine alone, azithromycin alone, or neither. Main Outcomes and Measures Primary outcome was in-hospital mortality. Secondary outcomes were cardiac arrest and abnormal electrocardiogram findings (arrhythmia or QT prolongation). Results Among 1438 hospitalized patients with a diagnosis of COVID-19 (858 [59.7%] male, median age, 63 years), those receiving hydroxychloroquine, azithromycin, or both were more likely than those not receiving either drug to have diabetes, respiratory rate >22/min, abnormal chest imaging findings, O2saturation lower than 90%, and aspartate aminotransferase greater than 40 U/L. Overall in-hospital mortality was 20.3% (95% CI, 18.2%-22.4%). The probability of death for patients receiving hydroxychloroquine + azithromycin was 189/735 (25.7% [95% CI, 22.3%-28.9%]), hydroxychloroquine alone, 54/271 (19.9% [95% CI, 15.2%-24.7%]), azithromycin alone, 21/211 (10.0% [95% CI, 5.9%-14.0%]), and neither drug, 28/221 (12.7% [95% CI, 8.3%-17.1%]). In adjusted Cox proportional hazards models, compared with patients receiving neither drug, there were no significant differences in mortality for patients receiving hydroxychloroquine + azithromycin (HR, 1.35 [95% CI, 0.76-2.40]), hydroxychloroquine alone (HR, 1.08 [95% CI, 0.63-1.85]), or azithromycin alone (HR, 0.56 [95% CI, 0.26-1.21]). In logistic models, compared with patients receiving neither drug cardiac arrest was significantly more likely in patients receiving hydroxychloroquine + azithromycin (adjusted OR, 2.13 [95% CI, 1.12-4.05]), but not hydroxychloroquine alone (adjusted OR, 1.91 [95% CI, 0.96-3.81]) or azithromycin alone (adjusted OR, 0.64 [95% CI, 0.27-1.56]), . In adjusted logistic regression models, there were no significant differences in the relative likelihood of abnormal electrocardiogram findings. Conclusions and Relevance Among patients hospitalized in metropolitan New York with COVID-19, treatment with hydroxychloroquine, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. However, the interpretation of these findings may be limited by the observational design.